Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaited

Detalles Bibliográficos
Autores principales: Denis, Marc G., Herbreteau, Guillaume, Pons-Tostivint, Elvire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989810/
https://www.ncbi.nlm.nih.gov/pubmed/36895928
http://dx.doi.org/10.21037/tlcr-22-899
_version_ 1784901832113389568
author Denis, Marc G.
Herbreteau, Guillaume
Pons-Tostivint, Elvire
author_facet Denis, Marc G.
Herbreteau, Guillaume
Pons-Tostivint, Elvire
author_sort Denis, Marc G.
collection PubMed
description
format Online
Article
Text
id pubmed-9989810
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-99898102023-03-08 Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaited Denis, Marc G. Herbreteau, Guillaume Pons-Tostivint, Elvire Transl Lung Cancer Res Editorial AME Publishing Company 2023-01-19 2023-02-28 /pmc/articles/PMC9989810/ /pubmed/36895928 http://dx.doi.org/10.21037/tlcr-22-899 Text en 2023 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial
Denis, Marc G.
Herbreteau, Guillaume
Pons-Tostivint, Elvire
Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaited
title Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaited
title_full Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaited
title_fullStr Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaited
title_full_unstemmed Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaited
title_short Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaited
title_sort molecular minimal residual disease in resected non-small cell lung cancer (nsclc): results of specifically designed interventional clinical trials eagerly awaited
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989810/
https://www.ncbi.nlm.nih.gov/pubmed/36895928
http://dx.doi.org/10.21037/tlcr-22-899
work_keys_str_mv AT denismarcg molecularminimalresidualdiseaseinresectednonsmallcelllungcancernsclcresultsofspecificallydesignedinterventionalclinicaltrialseagerlyawaited
AT herbreteauguillaume molecularminimalresidualdiseaseinresectednonsmallcelllungcancernsclcresultsofspecificallydesignedinterventionalclinicaltrialseagerlyawaited
AT ponstostivintelvire molecularminimalresidualdiseaseinresectednonsmallcelllungcancernsclcresultsofspecificallydesignedinterventionalclinicaltrialseagerlyawaited

Ejemplares similares